GlassScriptPhysician profile
Nestor Punay
NPI 1801870522
$233,886.36
in general payments reported to CMS, 2019-2025
66 companies · $27K in 2025
The $27K reported for 2025 was more than what 94% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,883 · 2020: $26K · 2021: $62K · 2022: $51K · 2023: $32K · 2024: $33K · 2025: $27K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $80K · Food and Beverage: $11K · Travel and Lodging: $944 · Education: $179.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $79,756.25 |
| Food and Beverage | $10,953.25 |
| Travel and Lodging | $944.11 |
| Education | $178.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $185,585.34 | 2019-2025 | |
| Allergan, INC. | $25,038.78 | 2019-2021 | |
| Acadia Pharmaceuticals INC | $2,048.70 | 2019-2025 | Nuplazid |
| Biohaven Pharmaceutical Holding Company LTD. | $1,676.98 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $1,421.20 | 2019-2025 | Austedo Xr, Austedo Xr, Ajovy |
| Boston Scientific Corporation | $1,370.41 | 2021-2023 | Vercise |
| Lundbeck LLC | $1,250.40 | 2020-2025 | Vyepti, Rexulti |
| Emd Serono, INC. | $1,193.75 | 2019-2025 | Mavenclad, Mavenclad |
| Pfizer INC. | $1,073.95 | 2019-2025 | |
| Neuropace, INC. | $1,069.70 | 2024 | |
| Amneal Pharmaceuticals LLC | $826.66 | 2019-2025 | Rytary, Crexont, Ongentys 50mg Capsules 30 |
| Sunovion Pharmaceuticals INC. | $718.83 | 2019-2022 | |
| Neurocrine Biosciences, INC. | $712.57 | 2019-2025 | Ingrezza, Ongentys |
| Sk Life Science, INC. | $690.23 | 2020-2025 | Xcopri |
| Mallinckrodt Hospital Products INC. | $635.80 | 2020-2025 | Acthar |
Show all 66 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $619.91 | 2019-2023 | |
| Ucb, INC. | $609.92 | 2019-2023 | Briviact, Fintepla |
| Abbott Laboratories | $560.70 | 2019-2020 | |
| Lilly USA, LLC | $541.99 | 2019-2025 | Kisunla, Amyvid, Emgality |
| Supernus Pharmaceuticals, INC. | $497.37 | 2019-2022 | |
| Eisai INC. | $496.69 | 2019-2025 | |
| Otsuka America Pharmaceutical, INC. | $475.02 | 2023-2025 | Rexulti, Nuedexta |
| Biogen, INC. | $345.02 | 2019-2023 | Spinraza |
| Mdd US Operations, LLC | $331.19 | 2019-2020 | |
| Argenx US, INC. | $325.92 | 2022-2025 | Vyvgart, Vyvgart Hytrulo |
| Celgene Corporation | $303.98 | 2022-2025 | Zeposia |
| Novartis Pharmaceuticals Corporation | $302.74 | 2019-2025 | |
| Sumitomo Pharma America, INC. | $269.36 | 2023-2024 | Aptiom |
| Biohaven Pharmaceuticals, INC. | $252.28 | 2021 | |
| Amgen INC. | $197.87 | 2020-2022 | |
| Acorda Therapeutics, INC | $197.23 | 2019 | |
| Csl Behring | $195.86 | 2019-2021 | |
| Avion Pharmaceuticals | $156.50 | 2022-2023 | Dhivy |
| Impel Pharmaceuticals INC. | $140.92 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $139.53 | 2023-2024 | Hyqvia |
| Alexion Pharmaceuticals, INC. | $132.31 | 2019-2024 | Ultomiris |
| Corium, LLC | $127.92 | 2023 | Adlarity |
| Kyowa Kirin, INC. | $118.38 | 2022-2024 | Nourianz |
| Grifols USA, LLC | $116.21 | 2020-2024 | Gamunex-C |
| Livanova USA, INC. | $115.15 | 2022-2024 | Vns Therapy Sentiva Model 1000 Generator |
| Avanir Pharmaceuticals, INC. | $95.73 | 2020-2022 | |
| Janssen Pharmaceuticals, INC | $93.49 | 2019-2022 | |
| Ge Healthcare | $86.85 | 2020-2023 | |
| Arbor Pharmaceuticals, INC. | $79.66 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $61.69 | 2020-2021 | |
| Aquestive Therapeutics, INC. | $60.58 | 2020-2022 | |
| Upsher-Smith Laboratories LLC | $54.43 | 2019-2020 | |
| Akcea Therapeutics, INC. | $49.16 | 2019-2020 | |
| Zyla Life Sciences, INC. | $35.93 | 2019 | |
| Catalyst Pharmaceuticals, INC. | $35.35 | 2021-2022 | |
| Medtronic, INC. | $28.59 | 2021 | |
| Greenwich Biosciences, INC. | $27.81 | 2019-2020 | |
| Horizon Therapeutics Plc | $26.74 | 2023 | Uplizna |
| Mallinckrodt Enterprises LLC | $25.86 | 2019 | |
| Collegium Pharmaceutical, INC. | $24.19 | 2022 | |
| Genentech USA, INC. | $23.99 | 2020 | |
| Ani Pharmaceuticals, INC. | $23.63 | 2025 | Purified Cortrophin Gel |
| Insightec,INC | $22.74 | 2024 | Exablate |
| Assertio Therapeutics, INC. | $22.46 | 2019 | |
| Neurelis, INC. | $20.09 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $19.80 | 2021 | |
| Merck Sharp & Dohme LLC | $18.95 | 2021 | |
| Axsome Therapeutics, INC. | $18.93 | 2025 | Auvelity |
| Almatica Pharma LLC | $17.53 | 2021 | |
| Neuronetics, INC. | $14.91 | 2019 | |
| Currax Pharmaceuticals LLC | $14.00 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nestor Punay listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.